The Effectiveness of Narrow Band Uvb (Nb-Uvb) In the Treatment of Pityriasis Lichenoides Chronica (PLC) In Vietnam by Le Huu, Doanh et al.
 _______________________________________________________________________________________________________________________________ 
Open Access Maced J Med Sci. 2019 Jan 30; 7(2):221-223.                                                                                                                                                        221 
 
ID Design Press, Skopje, Republic of Macedonia 
Open Access Macedonian Journal of Medical Sciences. 2019 Jan 30; 7(2):221-223. 
Special Issue: Vietnamese Dermatology 
https://doi.org/10.3889/oamjms.2019.055 
eISSN: 1857-9655 
Clinical Science 
 
 
  
 
The Effectiveness of Narrow Band Uvb (Nb-Uvb) In the Treatment 
of Pityriasis Lichenoides Chronica (PLC) In Vietnam 
 
 
Doanh Le Huu
1,2
, Thao Ngo Minh
1
, Thuong Nguyen Van
1,2
, Phuong Pham Thi Minh
1
, Nghi Dinh Huu
1,2
, Van Tran Cam
1
, My 
Le Huyen
1
, Minh Vu Nguyet
1,2
, Mai Le Thi
1
, Hien Do Thi Thu
1
, Khang Tran Hau
1,2
, Marco Gandolfi
3*
, Francesca Satolli
3
, 
Claudio Feliciani
3
, Michael Tirant
4,5
, Aleksandra Vojvodic
6
, Torello Lotti
4
 
 
1
National Hospital of Dermatology and Venereology, Hanoi, Vietnam; 
2
Hanoi Medical University, Vietnam; 
3
Unit of 
Dermatology, University of Parma, Parma, Italy; 
4
University of Rome G. Marconi, Rome, Italy; 
5
Psoriasis Eczema Clinic, 
Melbourne, Australia; 
6
Department of Dermatology and Venereology Military Medical Academy, Belgrade, Serbia 
 
Citation: Le Huu D, Ngo Minh T, Van TN, Thi Minh PP, 
Dinh Huu N, Tran Cam V, Le Huyen M, Vu Nguyet M, Le 
Thi M, Thi Thu HD, Tran Hau K, Gandolfi M, Satolli F, 
Feliciani C, Tirant M, Vojvodic A, Lotti T. TheEffectiveness 
of Narrow Band Uvb (Nb-Uvb) In the Treatment of 
Pityriasis Lichenoides Chronica (Plc) In Vietnam. Open 
Access Maced J Med Sci. 2019 Jan 30; 7(2):221-223. 
https://doi.org/10.3889/oamjms.2019.055 
Keywords: Phototherapy; NB-UVB; Pityriasis lichenoides 
chronica; Effectiveness; Safety 
*Correspondence: Marco Gandolfi. Unit of Dermatology, 
University of Parma, Parma, Italy. E-mail: 
marco.gandolfi5@gmail.com 
Received: 02-Jan-2019; Revised: 16-Jan-2019; 
Accepted: 17-Jan-2019; Online first: 25-Jan-2019 
Copyright: © 2019 Doanh Le Huu, Thao Ngo Minh, 
Thuong Nguyen Van, Phuong Pham Thi Minh, Nghi Dinh 
Huu, Van Tran Cam, My Le Huyen, Minh Vu Nguyet, Mai 
Le Thi, Hien Do Thi Thu, Khang Tran Hau, Marco 
Gandolfi, Francesca Satolli, Claudio Feliciani, Michael 
Tirant, Aleksandra Vojvodic, Torello Lotti. This is an open-
access article distributed under the terms of the Creative 
Commons Attribution-NonCommercial 4.0 International 
License (CC BY-NC 4.0) 
Funding: This research did not receive any financial 
support 
Competing Interests: The authors have declared that no 
competing interests exist 
 
 
 
Abstract 
AIM: This prospective clinical study presents the experiences with NB-UVB monotherapy in the treatment of PLC 
on Vietnamese patients. 
METHODS: We enrolled at National Hospital of Dermatology and Venereology (NHDV), Vietnam, 29 PLC 
patients with generalised disease involving at least 60% of the total body surface (based on Nine’s Rule) and/or 
failed to respond to other modalities of treatment. Patients were treated with NB-UVB followed the guideline of the 
psoriatic treatment of AAD-2010, three times weekly.  
RESULTS: A complete response (CR) was seen in 24 out of 29 PLC patients (82.8%) with a mean cumulative 
dose of 9760.5 mJ/cm
2
 after a mean treatment period of 4.6 weeks (13.8 ± 7.4 exposures). Mild side effects were 
observed: 69% erythema minimum, 55.2% irritation related to dry skin. No severe side effects were seen during 
the study. No relapses occurred in 24 CR patients within a mean period of 3 months after the last treatment.  
CONCLUSION: NB-UVB therapy is an effective and safe option for the treatment and management of PLC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Pityriasis lichenoides chronica (PLC) is a 
chronic papulosquamous disorder of unknown 
aetiology with remissions and exacerbations. Although 
being a self-limited condition, therapeutic approach is 
required based on cosmetic and symptomatic 
concerns. Many treatment options including topical or 
systemic corticosteroids, oral tetracycline, topical 
calcineurin inhibitors such as tacrolimus, and 
methotrexate have been used with different success 
rates. NB-UVB phototherapy has recently 
demonstrated high levels of efficacy and tolerability in 
the treatment of patients with PL. Despite the variety 
of reports in the literature, no studies have been 
conducted to primarily evaluate the efficacy of such 
modality in PLC case series treatment.  
This prospective clinical study presents the 
experiences with NB-UVB monotherapy in the 
treatment of PLC on Vietnamese patients. 
 
 
Methods 
 
Twenty-nine Vietnamese patients, aged 3 to 
75 years old (11 males, 18 females, the initial mean 
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age of disease 25 ± 16.8 years old) were treated with 
NB-UVB mono-therapy. Treatment with NB-UVB (311 
nm) was given three times weekly in a Daavlin cabinet 
(Daavlin, CA, USA) equipped with Philips TL-01/100 
W fluorescent lamps (Philips Company, Eindhoven, 
the Netherlands). The initial and increasing treatment 
dose of NB-UVB in every treatment session depended 
on patients’ skin type classified by Fitzpatrick (AAD-
2010 guidelines). In the case of mild side-effects 
including mild to moderate erythema, burning 
sensation, the dose of NB-UVB was decreased by 
20%. In case of severe side-effects such as severe 
erythema, burning or photosensitivity, the treatment 
was stopped, and the patient was applied topical 
corticosteroids with an oral non-steroidal anti-
inflammatory drug (NSAID). If one to three sessions 
were missed, the dose was unchanged, and if more 
than four sessions were missed, the dose was 
decreased by 25% (within 7 sessions), 50% (from 8 to 
11 sessions) or began again (over 12 sessions). 
Complete response (CR) was defined as 
more than 90% resolution in skin lesions 
(papulosquamous and plaque lesions). Partial 
response (PR) was defined as the resolution of 50-
90% in skin lesions. Poor response (NR) was taken as 
less than 50% reduction in lesions. Patients were 
assessed every 6 sessions until they cleared skin 
lesions or after completed 36 sessions. If the patient’s 
skin lesions cleared before completing 36 treatment 
sessions, they were observed for at least 3 months to 
determine any recurrence. Detection of more than 10 
new lesions was defined as recurrence.  
Both thickness and scaling scores were 
assessed at the initial and at the end of treatment 
(PASI score). Patients also fulfilled a self-evaluation 
satisfaction questionnaire. 
 
 
Results 
 
After one month treatment (4.6 weeks), 82.8% 
complete response was achieved with the mean 
number of treatment sessions was 13.8 (range: 4-30 
sessions). The mean number of sessions required to 
achieve the first clinical response was 6.4 (range: 3-
14 sessions).  
 
Figure 1: Improvement of the total body surface in skin lesions 
Most patients had reduced the total body 
surface area (BSA) after 6 sessions (p < 0.001). The 
improvement of skin had seen and maintained after 
12 sessions (p < 0.001) as shown in Figure 1.  
Thickness, scale and pruritus of skin lesions 
had good improvement after the last session by NB-
UVB mono-therapy (p < 0.001) as shown in Figure 2. 
 
Figure 2: Improvement of thickness and scale of skin lesions 
 
The mean cumulative dose was 9760.5 
mJ/cm
2
. All patients have remained relapse-free for at 
least 3 months.  
A group of 27/29 patients treated with 
phototherapy reported minimal erythema (69%) and 
itchy (55.2%). These side effects have resolved 
quickly after topical emollients and irradiation dose 
reduction. None of the patients discontinued treatment 
as a result of side effects. 
All patients were satisfied with the treatment; 
more than 80% of the patients would recommend the 
procedure. 
 
 
Discussion 
 
In National Hospital of Dermatology and 
Venereology (NHDV), 29 patients with PLC (11 males 
and 18 females) with the initial mean age of disease 
was 25 ± 16,8 years and mean disease duration was 
39,9 ± 57,9 months. This is convenient with criteria 
chronic and most commonly occurs in children and 
young adults of PLC. Responses to various treatment 
modalities, such as topical corticosteroids and oral 
antibiotics were extremely poor despite diffuse skin 
lesions. Topical corticosteroids are unable to affect 
the course of disease whereas systemic antibiotics, 
including erythromycin and tetracycline, have been 
used for their anti-inflammatory rather than antibiotic 
effects [1], [2].  
The exact mechanism of NB-UVB for a 
phototherapeutic treatment modality for PL, including 
PLC is unknown. In the previous studies, NB-UVB has 
been shown to be the safe and effective treatment 
option for several inflammatory and neoplastic skin 
diseases characterised by epithelial and dermal 
infiltrates rich in T lymphocytes. In chronic plaque 
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psoriasis, NB-UVB mono-therapy could reduce the 
number of activated T cells by inducing T cells 
apoptosis [3]. Recent studies have revealed that UVB 
suppresses the all activating and antigen-presenting 
capacity of epidermal Langerhans cells and therefore 
UVB modulates the circulating cytokines accounts, 
such as IL-1, IL-6, IL-8, IL-12 and TNF-α production 
by human keratinocytes due to immunosuppression 
[4]. The expression of ICAM-1 has been suppressed 
in cultured human keratinocytes, and decreases the 
release of histamine from mast cells by systemic 
UVB-induced, in turn, decrease the itch response of 
skin lesions [5]. In the present study, 29 PLC patients 
were treated with NB-UVB monotherapy. 82.8% of 
patients achieved a CR within 13.8 ± 7.4 sessions (4, 
6 weeks) of their first therapy session. Thickness, 
scale and pruritus of skin lesions were reported 
reducing after finished treatment. No patients relapsed 
during the follow-up (for at least 3 months after the 
last treatment). These results, compared with the 
published data, demonstrated that NB-UVB therapy 
should be highly recommended for PLC treatment.  
Similarly, several studies demonstrated the 
efficacy of NB-UVB phototherapy in PLC treatment. 
Farnaghi et al. described their experience with NB-
UVB in eight PLC patients. CR was achieved by 
87.5% (7/8) of the patients within a mean number of 
37 ± 11 treatments [6]. Fernandez at al. has reported 
on 8 adults diffuse PLC patients whose disease 
showed no response to topical therapy. A CR rate of 
88% in a mean of 23 sessions (cumulative dose 16,99 
J/cm
2
) was obtained [7]. Ersoy et al. reported on 25 
PLC patients (14 male, 11 female). CR was achieved 
in 48% of the patients after 25 sessions (8 weeks) of 
the median number treatment [8]. Although the 
relapse-free rates after NB-UVB monotherapy varied 
from 42 to 73% in the literature, the discrepancy in 
relapse rates between previous studies and the 
present study may reflex differences both in the length 
of follow-up periods and in the choice of the initial and 
increasing dose in every session treatment. In the 
current study, NB-UVB phototherapy proved to be 
safe modality in the treatment of PLC patients. Short-
term adverse effects showed minimal erythema and 
itch in most patients which could be quickly resolved 
while long-term adverse effects were unavailable.  
In conclusion, NB-UVB therapy is an effective 
and safe option for the treatment and management of 
PLC. It also has several advantages over treatment 
with BB-UVB and PUVA. So NB-UVB should be 
considered as the first line in generalised cases 
interested in treatment. 
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